Status:

WITHDRAWN

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

Lead Sponsor:

University of Colorado, Denver

Conditions:

Femoroacetabular Impingement

Chondral Lesions

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

The purpose of this research project is to assess the effectiveness of intra-articular injections of autologous platelet-rich plasma (PRP) after arthroscopic microfracture. Our hypothesis is that plat...

Detailed Description

The purpose of this research project is to assess the effectiveness of intra-articular injections of autologous platelet-rich plasma (PRP) after arthroscopic microfracture. Our hypothesis is that plat...

Eligibility Criteria

Inclusion

  • Male or female patients aged 18-50, inclusive.
  • Healthy patients undergoing hip arthroscopy due to FAI.
  • No OA according to X-Ray, defined by the presence of joint space narrowing, osteophytes, sclerosis and subchondral cysts and surgery observation (Tonnis grade 0-1).
  • No other influential disabilities in lower limbs, which could alter the post-operative therapy.
  • No chronic use of NSAIDs, steroids, or chemotherapy drugs during the last 6 months before enrollment.
  • Women of childbearing potential will be allowed to enroll but must be willing to practice one highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device \[IUD\] or intrauterine system \[IUS\] condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study.
  • Intra-articular cartilage lesion grade 2-3-4-5 of Beck Classification or III-IV of Outerbridge.

Exclusion

  • Patients with autoimmune concomitant disease(s) that may affect joints, such as rheumatoid arthritis (RA), psoriatic arthritis and lupus arthritis.
  • Patients with polyarticular disease.
  • Patients with major conditions, such as poorly controlled diabetes, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or untreated depression.
  • Patients with blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin \<9g/dL).
  • Patients who had intra-articular treatment with steroids within 6 months of enrollment in this study or received more than 3 previous intra-articular steroid injections to the effected hip.
  • Patients who are pregnant or nursing at the time of consent.
  • Non-English speaking patients. (Scores used for evaluation have not been validated in Spanish).
  • Patients who had previous hip surgery.
  • Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.
  • Chronic use of NSAIDs (defined as taking NSAID regularly every week for the last 6 months), steroids or chemotherapy drugs.
  • Patients with a BMI over 30. Due to the fact that this study utilizes an injection technique, which may be inaccurate in obese subjects.
  • Patients with pacemakers or metal implants who are unable to get an MRI.
  • Non-adherence according to inclusion criteria.
  • Patients allergic to lidocaine

Key Trial Info

Start Date :

July 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2015

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02183896

Start Date

July 1 2014

End Date

July 1 2015

Last Update

December 28 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado Denver, CU Sports Medicine

Boulder, Colorado, United States, 80304